Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2023; 18(03): 533-538
DOI: 10.1055/s-0043-1771369
Original Article

A 10-Year Survival-Trend Analysis of Low-Grade Glioma and Treatment Patterns from an LMIC

Mohammad Hamza Bajwa 
1   Department of Surgery, The Aga Khan University, Karachi, Pakistan
,
Saad Bin Anis
2   Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
,
Irfan Yousaf 
2   Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
,
Mashal Shah
1   Department of Surgery, The Aga Khan University, Karachi, Pakistan
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objectives The 2021 WHO Classification of Central Nervous System Tumors taxonomy laid further stress on molecular classification and prognostication of glial tumors in comparison to histopathological grading. Research shows that low-grade gliomas (LGGs) can go through malignant differentiation and lead to severe disability and death. Data from various populations will be necessary to ascertain the exact interplay between genotypic predictors of LGG and outcomes.

Materials and Methods To assess the molecular pathology for glial tumors in the Pakistani population, the Shaukat Khanum Memorial Cancer Hospital carried out a retrospective chart review of electronic health records from 2008 to 2018, with immunohistochemistry analysis findings from 2010 to 2018. Patients with a pathological diagnosis of a glioma were included.

Statistical Analysis Analysis was performed using IBM SPSS Statistics Version 23 and STATA Version 16. A p-value of less than 0.05 was considered statistically significant with 95% confidence intervals reported.

Results In all, 281 operable tumors were recorded. The most common procedure was a subtotal resection, and astrocytomas (64.77%) were the most common tumors. Radiation therapy and PCV (procarbazine, CCNU, and vincristine) was received by 85 patients, while radiation therapy and temozolomide were administered to 15 patients.

Conclusions Isocitrate dehydrogenase (IDH) wild-type LGG had a lower survival time, while improved survival times were seen for alpha-thalassemia X-linked intellectual disability syndrome (ATRX) retained and 1p19q co-deleted LGGs. Further studies are required to gain a better understanding of lower-grade glial tumor treatment and survival in Pakistan.

Keywords

brain tumor - epidemiology - glioma - LMIC - low-grade glioma

Author Contribution

All authors contributed to the study conception and design. Material preparation and data collection were performed by SBA and IY. Analysis was done by MHB, MS, and SBA. The first draft of the manuscript was written by MHB, MS, and SBA, and all the authors commented on previous versions of the manuscript. All the authors read and approved the final manuscript.


Ethical Approval

Prior to initiation of this study, ethical approval, and exemption was granted by the IRB (Institutional Review Board) at the Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan.




Publication History

Article published online:
22 September 2023

© 2023. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hayhurst C. Contemporary management of low-grade glioma: a paradigm shift in neuro-oncology. Pract Neurol 2017; 17 (03) 183-190
    CrossrefPubMedSearch in Google Scholar
  • 2 Kumthekar P, Raizer J, Singh S. Low-grade glioma. Cancer Treat Res 2015; 163: 75-87
    CrossrefPubMedSearch in Google Scholar
  • 3 Bukhari SS, Shamim MS. Can awake glioma surgery be the new standard of care in developing countries?. Surg Neurol Int 2020; 11: 434
    CrossrefPubMedSearch in Google Scholar
  • 4 Chammas M, Saadeh F, Maaliki M, Assi H. Therapeutic interventions in adult low-grade gliomas. J Clin Neurol 2019; 15 (01) 1-8
    CrossrefPubMedSearch in Google Scholar
  • 5 Tom MC, Cahill DP, Buckner JC, Dietrich J, Parsons MW, Yu JS. Management for different glioma subtypes: are all low-grade gliomas created equal?. Am Soc Clin Oncol Educ Book 2019; 39: 133-145
    CrossrefPubMedSearch in Google Scholar
  • 6 Houillier C, Wang X, Kaloshi G. et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75 (17) 1560-1566
    CrossrefPubMedSearch in Google Scholar
  • 7 Iwadate Y, Matsutani T, Hara A. et al. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. J Neurooncol 2019; 141 (01) 205-211
    CrossrefPubMedSearch in Google Scholar
  • 8 Eseonu CI, Eguia F, ReFaey K. et al. Comparative volumetric analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival. J Neurooncol 2017; 134 (01) 65-74
    CrossrefPubMedSearch in Google Scholar
  • 9 Kinslow CJ, Garton ALA, Rae AI. et al. Extent of resection and survival for oligodendroglioma: a U.S. population-based study. J Neurooncol 2019; 144 (03) 591-601
    CrossrefPubMedSearch in Google Scholar